🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

132 results for “Boehringer Ingelheim International GmbH” Clear

  1. A study in healthy people to compare how 2 different low dose formulations of BI 1015550 are taken up in the body

    Boehringer Ingelheim International GmbH

    Pharmacokinetic trial

    phase 1 other active

    1 trial

  2. A study in healthy people to compare how 3 different formulations of survodutide are taken up in the body

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  3. A study in healthy people to compare two different Sifrol® tablets

    Boehringer Ingelheim International GmbH

    Pharmacokinetic trial

    phase 1 other active

    1 trial

  4. A study in healthy people to compare two different tablets of BI 685509 and to test how food and esomeprazole influence the amount of BI 685509 in the blood

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  5. A study in healthy people to compare two tablet formulations of pramipexole

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  6. A study in healthy people to see how zongertinib is taken up into the blood when given as tablets made by two different manufacturers

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  7. A study in healthy people to test how 2 different doses of BI 1291583 are taken up in the body when given in 3 different formulations.

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  8. A study in healthy people to test how 2 different formulations of BI 690517 are taken up in the body and how probenecid influences the amount of BI 690517 in the blood

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  9. A study in healthy people to test how 3 different formulations of BI 764198 are taken up in the body and how this is influenced by food

    Boehringer Ingelheim International GmbH

    healthy volunteer trial

    phase 1 other active

    1 trial

  10. A study in healthy people to test how BI 1015550 is taken up in the body when given with or without food

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  11. A study in healthy people to test how empagliflozin is taken up in the body when taken as a whole tablet or dissolved in water and mixed with food

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  12. A study in healthy people to test how itraconazole influences the amount of BI 3031185 in the blood

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  13. A study in healthy people to test how vicadrostat affects the heart

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  14. A study in healthy people to test how well different doses of BI 3000202 are tolerated and how they affect the way the body handles midazolam

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  15. A study in healthy people to test whether BI 1291583 influences the amount of dabigatran in the body

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  16. A study in healthy people to test whether BI 3000202 affects how 2 other medicines (rosuvastatin and digoxin) are taken up in the body

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  17. A study in healthy people to test whether BI 764198 influences the amount of metformin in the body

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  18. A study in healthy people to test whether erythromycin influences the amount of BI 1291583 in the blood.

    Boehringer Ingelheim International GmbH

    Healthy volunteer trial

    phase 1 other active

    1 trial

  19. A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab) and BI 754111 or BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab)

    Boehringer Ingelheim International GmbH

    advanced solid tumors

    phase 1 other active

    1 trial

  20. A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps

    Boehringer Ingelheim International GmbH

    Melanoma, Solid tumours

    phase 1 other active

    1 trial

  21. A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab

    Boehringer Ingelheim International GmbH

    unresectable advanced or metastatic solid cancer

    phase 1 other active

    1 trial

  22. A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor

    Boehringer Ingelheim International GmbH

    Solid cancer tumors

    phase 1 other active

    1 trial

  23. A study in people with obesity to test the effects of different doses of BI 456906 compared with semaglutide on glucagon receptor activity in the liver

    Boehringer Ingelheim International GmbH

    No targeted indication. Male and female subjects with obesity.

    phase 1 other active

    1 trial

  24. A study in people with overweight or obesity to test how BI 1820237, BI 456906, or a combination of both affects brain activity

    Boehringer Ingelheim International GmbH

    Obesity

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources